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mate) in 45 pts following CT.
Conclusions: Deﬁbrotide in pts with VOD was generally well
tolerated in this population, with manageable toxicity and
promising response rates and survival. Safety results from
prior studies are consistent with the favorable tolerability
proﬁle seen in this largest experience to date. Enrollment to
the T-IND study continues, with updated results to be pre-
sented at the meeting.
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Introduction: Hepatic veno-occlusive disease (VOD) is a
serious complication of hematopoietic stem cell trans-
plantation (HSCT) and, in severe cases, is associated with
multi-organ failure and mortality rates exceeding 80%. In the
US there are currently no FDA-approved treatments for se-
vere VOD. Deﬁbrotide, an oligonucleotide with a mechanism
of action that encompasses both restoration of the thrombo-
ﬁbrinolytic balance and endothelial cell protection, has
recently been approved for the treatment of severe VOD
following HSCT in the EU. The data presented are based on
the primary and secondary endpoint analyses provided to
the European Medicines Agency (EMA) that formed the basis
of the deﬁbrotide approval in the EU.
Methods: A pivotal phase 3 study examined the efﬁcacy and
safety of deﬁbrotide 25 mg/kg/day in patients with severe
VOD (n¼102) compared to historical controls (n¼32). The
study’s primary endpoint was complete response (CR) (in
terms of improvements in total bilirubin and resolution of
multi-organ failure measured by renal and/or pulmonary
dysfunction) by 100 days post-HSCT; secondary endpoints
included survival 100 days and 180 days post-HSCT. We
calculated the number needed to treat (NNT) with deﬁbro-
tide to achieve one complete response and the NNT to pre-
vent one death 100 days post-HSCT in patients with severe
VOD compared to historical controls who did not receive
deﬁbrotide in order to evaluate how deﬁbrotide compared to
other efﬁcacious treatments for acute, life-threatening con-
ditions. NNT is calculated as the reciprocal of the absolute
risk reduction (1/ARR), where ARR is equal to the control
minus experimental event rates.
Results: In the deﬁbrotide trial, complete response by day
100 was achieved in 23.5% of the deﬁbrotide-treated patients
and 9.4% of the historical controls (P¼0.013), which equated
to an NNT of 7 (1/(0.235-0.094)) to achieve one complete
response 100 days post-HSCT. Day 100 survival was 38.2% in
the deﬁbrotide group and 25.0% in the historical control
group (P¼0.034). Therefore, the NNT to prevent one death in
this study was 8 (1/(0.382-0.25)). To compare the NNTs in
this analysis with those in other studies, a literature searchwas conducted, identifying recent clinical trials in acute
conditions with high short-term mortality. NNTs calculated
from that review ranged from 1 to 59.
Conclusion: The results of this pivotal Phase 3 trial showed
improved complete response and survival in deﬁbrotide-
treated patients compared to historical controls who did not
receive deﬁbrotide for the treatment of severe VOD. The
number needed to treat to achieve this beneﬁt proved either
comparable to or lower than the NNT obtained for other
widely accepted and approved therapeutic medical in-
terventions in critical care.
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Background: Human metapneumovirus (HMPV) is a respi-
ratory virus that was ﬁrst identiﬁed in 2001. In immuno-
compromised hosts, HMPV upper respiratory tract infection
(URI) can progress to lower respiratory tract disease (LRD).
The mortality rate after HMPV LRD in hematopoietic cell
transplant (HCT) recipients is as high as 40%, similar to that of
respiratory syncytial virus, a structurally similar respiratory
virus. To date, most studies in HCT recipients are of very
small sample size, and minimal data exists on risk factors for
LRD. Here we analyzed the seasonality of HMPV infections as
well as patient, transplant and viral risk factors for progres-
sion to LRD.
Methods: This retrospective cohort study included HCT re-
cipients with HMPV documented by RT-PCR transplanted
between 2004 and 2014 at FHCRC. To detect HMPV, naso-
pharyngeal, bronchoalveolar lavage (BAL) or lung biopsy
samples were tested by quantitative PCR with or without
culture or direct ﬂuorescent antibody staining. LRD was
deﬁned as detection of HMPV in a BAL or biopsy sample with
new pulmonary inﬁltrates. Patients diagnosed with LRD  2
days after URI diagnosis were considered to have progression
